Viral Safety and Clearance in Bioprocessing Course

Name: Advanced Viral Safety and Clearance in Bioprocessing Training Course
Availability: InStock

Design, review, and govern risk-based viral clearance studies across biopharmaceutical process lifecycles.

Viral Safety and Clearance in Bioprocessing Course

At a glance

Duration: 1 Week
Format: Classroom
Cities: Amman, Cairo, Langkawi, London, Tbilisi, New York and more
Next session: 1 – 5 November 2026, Amman
Average fee: 5,750 €

Home
Our Categories
Advanced Viral Safety and Clearance in Bioprocessing Training Course

Overview

Advanced Viral Safety and Clearance in Bioprocessing Training Course is a one-week course for biopharmaceutical manufacturing, quality, validation, process development, biosafety, and regulatory affairs functions who leave with a Viral Safety Strategy and Clearance Study Dossier. Participants connect adventitious-agent risk, cell substrates, raw materials, orthogonal clearance steps, scale-down models, spiking studies, reduction-factor interpretation, robustness, deviations, and lifecycle evidence. Agile Leaders Training Center presents viral safety evaluation as a cross-functional bioprocess governance discipline.

Who Should Attend

Functions responsible for bioprocess design, characterization, and technical transfer
Quality functions reviewing viral safety evidence and lifecycle controls
Validation functions planning and governing clearance studies
Manufacturing functions controlling raw materials and process parameters
Biosafety and laboratory functions managing adventitious-agent risk and assays
CMC and regulatory functions assembling and reviewing technical evidence

The course assumes participants already support biological-product development, manufacturing, quality, validation, or technical submissions and leaves out introductory virology, viral-vector production, and promises of regulatory acceptance.

Departments and Industries

The course supports departments and industries that design, execute, review, or govern viral safety controls.

Biopharmaceutical and biotechnology manufacturing
Contract development and manufacturing organizations
Process development, MSAT, and manufacturing departments
Quality assurance, quality control, and validation departments
Biosafety, analytical development, and laboratory operations
CMC, technical documentation, and regulatory affairs functions

Learning Objectives

By the end of this course, participants will be able to:

Analyze viral contamination pathways across materials, substrates, and processing
Build an orthogonal viral clearance strategy
Evaluate model-virus and scale-down-model rationale
Use spiking, sampling, assay, and reduction-factor evidence
Diagnose robustness, deviation, and study-report weaknesses
Prioritize lifecycle changes and cross-functional actions

Course Agenda

Day 1: Viral Safety Risk and Scope

ICH Q5A(R2) Scope and Applicability Map
Viral Safety Triad Control Model
Cell Substrate and Raw Material Risk Register
Adventitious-Agent Pathway Analysis
Product and Process Scope Decision Record

Day 2: Clearance Process Design

Orthogonal Inactivation and Removal Matrix
Low-pH Inactivation Parameter Map
Virus Filtration Capability Assessment
Chromatography Clearance Mechanism Review
Clearance Step Independence Test

Day 3: Study Design and Scale-Down

Model Virus Selection Rationale
Scale-Down Model Qualification Protocol
Virus Spiking and Sampling Plan
Assay Suitability and Detection Strategy
Worst-Case Parameter Study Matrix

Day 4: Evidence and Lifecycle Governance

Log Reduction Factor Calculation Sheet
Clearance Data Uncertainty Review
Robustness and Step Contribution Analysis
Deviation and Invalid-Run Decision Tree
Process Change Impact Assessment

Day 5: Viral Clearance Practice

Exercise: Build a Viral Risk Register
Exercise: Qualify a Scale-Down Model
Exercise: Interpret Reduction-Factor Evidence
Exercise: Evaluate a Study Deviation Report
Capstone Exercise: Viral Safety Strategy and Clearance Study Dossier

Practical Exercises

The course uses suggested activities from monoclonal-antibody, recombinant-protein, and contract-manufacturing settings.

Suggested activity: map materials, substrates, process stages, contamination pathways, controls, owners, and evidence in a viral risk register.
Suggested activity: assess model-virus selection, scale-down comparability, spiking controls, sampling points, and assay suitability for a proposed study.
Suggested activity: calculate and interpret reduction factors while documenting uncertainty, robustness, limitations, and step independence.
Suggested activity: assemble risk, study-design, evidence-review, deviation, change-impact, and governance artifacts in the capstone dossier.

FAQs

Who suits advanced viral safety and clearance in bioprocessing training, and what does it assume?

Advanced viral safety and clearance in bioprocessing training suits experienced development, MSAT, manufacturing, quality, validation, biosafety, laboratory, CMC, and regulatory personnel who already support biological-product processes or evidence.

How does viral safety and clearance training differ from introductory bioprocess safety training?

Viral safety and clearance training concentrates on risk strategy, orthogonal clearance, study models, spiking controls, reduction factors, robustness, deviations, and lifecycle evidence rather than general biological-safety awareness.

What is an orthogonal viral clearance strategy in bioprocessing?

An orthogonal viral clearance strategy combines process steps with different removal or inactivation mechanisms so that the overall evidence does not depend on one mechanism alone.

Why are scale-down models used in viral clearance studies?

Scale-down models reproduce relevant full-scale process conditions at a manageable study scale, allowing controlled virus-spiking work while requiring documented comparability, limitations, and parameter rationale.

Does viral clearance evidence guarantee regulatory acceptance?

Viral clearance evidence does not guarantee acceptance; it supports a risk-based evaluation when study design, model suitability, controls, results, limitations, and lifecycle governance are scientifically justified.

Conclusion

The course connects viral risk, clearance-process design, study controls, evidence interpretation, deviations, and lifecycle governance. Participants take back a Viral Safety Strategy and Clearance Study Dossier containing risk, model, study, calculation, review, and change-control tools. The dossier helps teams coordinate decisions, test evidence quality, and document limitations without treating outcomes as predetermined.

credits: 5 credit per day

Course Mode: full-time

Provider: Agile Leaders Training Center

Download Brochure (PDF) Print PDF

Showing 21-40 of 75 events

Location	Dates	Duration	Mode	Price
Munich	Week 05, 2027 1 – 5 February 2027	1 Week	Onsite	€5,700
Amsterdam	Week 06, 2027 8 – 12 February 2027	1 Week	Onsite	€5,700
Vienna	Week 07, 2027 15 – 19 February 2027	1 Week	Onsite	€5,700
Toronto	Week 07, 2027 21 – 25 February 2027	1 Week	Onsite	€12,000
Lagos	Week 08, 2027 28 February – 4 March 2027	1 Week	Onsite	€4,100
Paris	Week 10, 2027 8 – 12 March 2027	1 Week	Onsite	€5,700
Singapore	Week 10, 2027 8 – 12 March 2027	1 Week	Onsite	€5,700
Abu Dhabi	Week 11, 2027 15 – 19 March 2027	1 Week	Onsite	€4,700
Geneva	Week 11, 2027 21 – 25 March 2027	1 Week	Onsite	€6,200
London	Week 12, 2027 22 – 26 March 2027	1 Week	Onsite	€5,700
Johannesburg	Week 12, 2027 28 March – 1 April 2027	1 Week	Onsite	€4,500
Amsterdam	Week 14, 2027 5 – 9 April 2027	1 Week	Onsite	€5,700
Bangkok	Week 14, 2027 11 – 15 April 2027	1 Week	Onsite	€6,000
Istanbul	Week 15, 2027 12 – 16 April 2027	1 Week	Onsite	€4,500
Madrid	Week 16, 2027 19 – 23 April 2027	1 Week	Onsite	€5,700
Frankfurt	Week 17, 2027 26 – 30 April 2027	1 Week	Onsite	€5,700
Kuwait	Week 17, 2027 2 – 6 May 2027	1 Week	Onsite	€5,500
Rome	Week 18, 2027 3 – 7 May 2027	1 Week	Onsite	€5,700
Tashkent	Week 18, 2027 9 – 13 May 2027	1 Week	Onsite	€4,500
Marbella	Week 19, 2027 16 – 20 May 2027	1 Week	Onsite	€5,700

Frequently asked questions

What does this course cover?

OverviewAdvanced Viral Safety and Clearance in Bioprocessing Training Course is a one-week course for biopharmaceutical manufacturing, quality, validation, process development, biosafety, and regulatory affairs functions who leave with a Viral Safety Strategy and Clearance Study Dossier. Participants connect adventitious-agent risk, cell substrates, raw m…

Are training dates available?

Yes. Available dates and destinations are listed in the course dates section on this page.

How can I register?

Choose an available date on this page and complete the registration form, or send a programme enquiry.

Can I download the course brochure?

Yes. Use the brochure download link provided on this page.

Viral Safety and Clearance in Bioprocessing Course